{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:45:22Z","timestamp":1793760322228,"version":"4.6.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T00:00:00Z","timestamp":1507593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0185642","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T13:28:44Z","timestamp":1507642124000},"page":"e0185642","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-4020","authenticated-orcid":true,"given":"Shuk-Li","family":"Collings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinira","family":"Lef\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7994-2380","authenticated-orcid":true,"given":"Michelle E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Hack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Stynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,10,10]]},"reference":[{"key":"ref1","unstructured":"National Institute for Health and Clinical Excellence. Atrial fibrillation: management. 2014."},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"SS Chugh","year":"2014","journal-title":"Circulation"},{"issue":"8","key":"ref3","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/hrt.2005.069492","article-title":"Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care","volume":"92","author":"S DeWilde","year":"2006","journal-title":"Heart"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/eurheartj\/eht483","article-title":"Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke","volume":"35","author":"JP Piccini","year":"2014","journal-title":"Eur Heart J"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"PA Wolf","year":"1991","journal-title":"Stroke"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus Warfarin in Patients with Atrial Fibrillation","volume":"365","author":"CB Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"MR Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"SJ Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"ref9","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","article-title":"The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation","volume":"323","year":"1990","journal-title":"N Engl J Med"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/clc.22204","article-title":"Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation","volume":"37","author":"I Savelieva","year":"2014","journal-title":"Clin Cardiol"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1161\/CIRCOUTCOMES.113.000192","article-title":"Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin","volume":"6","author":"M Zalesak","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCOUTCOMES.110.937680","article-title":"Warfarin discontinuation after starting warfarin for atrial fibrillation","volume":"3","author":"MC Fang","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"22","key":"ref13","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"RP Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/europace\/euv068","article-title":"Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation","volume":"17","author":"AJ Camm","year":"2015","journal-title":"Europace"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.amjcard.2012.03.049","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation","volume":"110","author":"CS Miller","year":"2012","journal-title":"Am J Cardiol"},{"issue":"20","key":"ref16","first-page":"2141","article-title":"Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes","volume":"63","author":"EM Hylek","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.5414\/CPP47617","article-title":"Validity and representativeness of the \u201cDisease Analyzer\u201d patient database for use in pharmacoepidemiological and pharmacoeconomic studies","volume":"47","author":"H Becher","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref18","unstructured":"Summary of Product Characteristics: Xarelto 15mg film-coated tablets [Internet]. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/25592<\/ext-link>"},{"key":"ref19","unstructured":"Summary of Product Characteristics: Pradaxa 110 mg hard capsules [Internet]. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/20760<\/ext-link>"},{"key":"ref20","unstructured":"Summary of Product Characteristics: Eliquis 2.5 mg film-coated tablets [Internet]. [cited 2015 Sep 15]. Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/24988<\/ext-link>"},{"issue":"9","key":"ref21","doi-asserted-by":"crossref","first-page":"e011471","DOI":"10.1136\/bmjopen-2016-011471","article-title":"Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care","volume":"6","author":"ME Johnson","year":"2016","journal-title":"BMJ Open"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00228-015-1983-z","article-title":"Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation","volume":"72","author":"T Forslund","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/europace\/euu225","article-title":"Non-vitamin K antagonist oral anticoagulation agents in anticoagulant na\u00efve atrial fibrillation patients: Danish nationwide descriptive data 2011\u20132013","volume":"17","author":"JB Olesen","year":"2015","journal-title":"Europace"},{"issue":"9","key":"ref24","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/ijcp.12863","article-title":"Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a real-world observational study in the United States","volume":"70","author":"GYH Lip","year":"2016","journal-title":"Int J Clin Pract"},{"issue":"2","key":"ref25","article-title":"Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation","volume":"5","author":"X Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.18553\/jmcp.2016.22.11.1319","article-title":"Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Na\u00efve Nonvalvular Atrial Fibrillation","volume":"22","author":"JD Brown","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"suppl 1","key":"ref27","article-title":"Risk of bleeding with non-vitamin k antagonists and phenprocoumon in routine care patients with non-valvular atrial fibrillation","volume":"37","author":"S Hohnloser","year":"2016","journal-title":"Eur Heart J"},{"issue":"8","key":"ref28","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/europace\/euv421","article-title":"Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation","volume":"18","author":"J Beyer-Westendorf","year":"2016","journal-title":"Europace"},{"issue":"21","key":"ref29","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"AJ Camm","year":"2012","journal-title":"Eur Heart J"},{"issue":"13","key":"ref30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0735-1097(16)30770-7","article-title":"Changes over time in treatment persistence of oral anticoagulants in patients with non-valvular atrial fibrillation. ACC 2016","volume":"67","author":"C Lefevre","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2016.01.008","article-title":"Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States","volume":"38","author":"T Bancroft","year":"2016","journal-title":"Clin Ther"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"e0157769","DOI":"10.1371\/journal.pone.0157769","article-title":"Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States","volume":"11","author":"CI Coleman","year":"2016","journal-title":"PLoS One"},{"key":"ref33","first-page":"1","article-title":"Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience","author":"LA Simons","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"A415","DOI":"10.1016\/S0735-1097(14)60415-0","article-title":"Real world discontinuation rates with apixaban versus warfarin, dabigatran, or rivaroxaban among atrial fibrillation patients newly initiated on anticoagulation therapy: early findings. ACC 2014","author":"X Pan","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"ref35","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1185\/03007995.2015.1086993","article-title":"Adherence to and persistence with non-vitamin K-antagonist oral anticoagulants: does the number of pills per day matter?","volume":"31","author":"A Rubboli","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"ref36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ahj.2014.07.002","article-title":"Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"168","author":"EC O\u2019Brien","year":"2014","journal-title":"Am Heart J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0185642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:35:45Z","timestamp":1588970145000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0185642"}},"subtitle":[],"editor":[{"given":"Carmine","family":"Pizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,10]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0185642","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,10]]}}}